EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Engineering CAR‐Tregs with Phage‐Selected scFv Enables a New Paradigm for Immune Regulation

Fatih Noyan iD, Matthias Hardtke-Wolenski iD

BioEssays · 2026-07 · 48 (7)

DOI: 10.1002/bies.70164 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BioEssays, online erschienen am 15.07.2026. Verfasst von Fatih Noyan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Dept. of Gastroenterology, Hepatology, Infectious Disease and Endocrinology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Single-Chain Antibodies, T-Lymphocytes, Regulatory, Receptors, Chimeric Antigen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Regulatory T cells (Tregs) are central to immune tolerance, yet antigen‐specific cell therapies lag behind cytotoxic CAR‐T approaches. Most CAR‐Treg programs still use single‐chain variable fragments (scFvs) derived from monoclonal antibodies optimized for effector function, a bias that may promote CAR clustering, tonic signaling, and lineage instability. Here, we propose a phage‐first binder discovery framework for CAR‐Tregs and state testable hypotheses linking phage‐display selection pressures to scFv biophysical properties and Treg fate. We hypothesize that multi‐parameter selection and counter‐selection can enrich scFvs with moderate affinity, low polyspecificity, and improved framework stability, thereby lowering tonic signaling in defined backbone architectures and preserving FOXP3/TSDR stability under inflammatory stress. We outline a falsifiable two‐phase roadmap—bench triage followed by mechanistic and preclinical validation to determine how scFv properties, expression level, and intracellular signaling domains define an optimal tonic window for durable immune regulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Chain AntibodiesT-Lymphocytes, RegulatoryReceptors, Chimeric AntigenHumansAnimalsImmune ToleranceImmunotherapy, Adoptive

Stichwörter der Autor:innen

FOXP3Treg cellcell biologychimeric antigen receptorimmune systemimmune tolerancemonoclonal antibodyscfv antibodies

Substanzen

Single-Chain AntibodiesReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Dept. of Gastroenterology, Hepatology, Infectious Disease and Endocrinology, Hannover Medical School, Hannover, Germany.
  • Inst. of Medical Microbiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

ORCID-Profile: Fatih Noyan, Matthias Hardtke-Wolenski

Zitieren

APA

Noyan, F., & Hardtke-Wolenski, M. (2026). Engineering CAR‐Tregs with Phage‐Selected scFv Enables a New Paradigm for Immune Regulation. BioEssays, 48(7). https://doi.org/10.1002/bies.70164

Vancouver

Noyan F, Hardtke-Wolenski M. Engineering CAR‐Tregs with Phage‐Selected scFv Enables a New Paradigm for Immune Regulation. BioEssays. 2026;48(7). doi:10.1002/bies.70164

BibTeX
@article{Noyan2026,
  author = {Noyan, Fatih and Hardtke-Wolenski, Matthias},
  title = {Engineering CAR‐Tregs with Phage‐Selected scFv Enables a New Paradigm for Immune Regulation},
  journal = {BioEssays},
  year = {2026},
  volume = {48},
  number = {7},
  doi = {10.1002/bies.70164}
}
Kostenlos starten →